Reply to the article "Editorial comments on 'reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'", by P. A. Bunn Jr (Ann Oncol 2001; 12: 1339-1340).
Tjan-Heijnen
V C G
VC
Postmus
P E
PE
Ardizzoni
A
A
D019072:Antibiotic Prophylaxis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002939:Ciprofloxacin / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D003520:Cyclophosphamide / Q000009:adverse effects*; D004311:Double-Blind Method; D004317:Doxorubicin / Q000009:adverse effects*; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005047:Etoposide / Q000009:adverse effects*; D005334:Fever / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*; D010166:Palliative Care; D016032:Randomized Controlled Trials as Topic; D015575:Roxithromycin / Q000627:therapeutic use
D015575:Roxithromycin; D002939:Ciprofloxacin; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide